Several big developers will take the stage at the American Society of Hematology meeting to provide updates on a string of new blood thinners that are in the clinic. Johnson & Johnson [1], Bristol-Myers Squibb and Pfizer [2], Eli Lilly, Boehringer Ingelheim and Portola are all testing drugs that may claim a portion of the multibillion-dollar market for blood thinners, according to the Wall Street Journal. Atrial fibrillation is the biggest clinical target with the most money at stake, say analysts. Developers want to provide an alternative to warfarin [3], a drug with a history of serious side effects that limit its use to about half of all prospective patients.
- read the article [4] from The Wall Street Journal
ALSO: Shares of Germany's Bayer rose on data for its blood thinner. Release [5]
PLUS: Seattle Genetics revealed positive, early-stage data for SGN-33, an experimental therapy for AML. Release [6]
AND: Shares of Celgene plunged 15 percent on disappointing Revlimid data. Report [7]
Related Articles:
Pfizer partners with BMS in $1B deal. Report [2]
Links:
[1] http://www.fiercepharma.com/story/spotlight-gsks-arixtra-losing-rivaroxaban/2007-08-08
[2] http://www.fiercebiotech.com/story/pfizer-partners-with-bms-in-1b-deal/2007-04-26
[3] http://www.fiercebiotech.com/story/genetic-test-seen-big-step-personalized-meds/2007-09-18
[4] http://online.wsj.com/article/SB119725064671318856.html?mod=dist_smartbrief
[5] http://www.fiercebiotech.com/press-releases/press-release-three-pivotal-phase-iii-trials-show-superior-efficacy-rivaroxaban-over-
[6] http://www.fiercebiotech.com/press-releases/press-release-seattle-genetics-reports-multiple-complete-remissions-sgn-33-acute-myel
[7] http://www.chron.com/disp/story.mpl/ap/fn/5365316.html